Novo Nordisk on Tuesday announced plans to cut the list price of its popular diabetes and weight-loss drugs Ozempic and Wegovy by as much as 50% in the U.S. next year. The Danish drugmaker indicated the price cuts will be effective on Jan. 1, 2027, and the timing will coincide with new, lower prices for Ozempic and Wegovy under Medicare plans for older Americans.The company's announcement indicated the list price for various doses of its Ozempic and Wegovy medicines will be lowered to $675, which represents ...

Group 1 - Hims & Hers, a telehealth provider known for compounded weight-loss drugs, has issued a weak outlook for the future [1] - The company is facing challenges that may impact its growth trajectory and financial performance [1] - Investors are concerned about the sustainability of the company's business model in a competitive market [1] Group 2 - The telehealth industry is experiencing increased scrutiny and regulatory challenges, which may affect companies like Hims & Hers [1] - Market dynamics are shifting, with a growing emphasis on transparency and efficacy in telehealth services [1] - The outlook for telehealth providers may be influenced by broader healthcare trends and consumer preferences [1]

This story was originally published on Retail Dive. To receive daily news and insights, subscribe to our free daily Retail Dive newsletter. It’s been another week with far more retail news than there is time in the day. Below, we break down some things you may have missed during the week and what we’re still thinking about. From Crate & Barrel’s collaboration with Converse to Hims & Hers’ latest acquisition, here’s our closeout for the week. What you may have missed New Balance brought in a record $9 ...

Group 1 - Hims & Hers has agreed to acquire digital health company Eucalyptus for $1.15 billion to expand its geographic reach [1] - The transaction involves an upfront payment of $240 million in cash, with the remainder consisting of deferred payments and contingent payments tied to specific financial targets by early 2029 [1] - The acquisition will enable Hims & Hers to enter the Australian and Japanese markets while expanding its existing operations in the UK, Germany, and Canada [1] Group 2 - Hims & Hers plans to enhance its local professional teams and upgrade infrastructure to replicate its successful U.S. model globally, aiming to reach millions of users [1] - The deal is expected to be completed by mid-2026, with Eucalyptus CEO Tim Doyle overseeing Hims & Hers' international business post-acquisition [1] - Hims & Hers is currently facing a lawsuit from Novo Nordisk, which seeks to prohibit the sale of its generic weight loss drugs, alleging patent infringement [2]

Core Insights - Traders are focusing on heavily shorted stocks, either betting on a company's decline or seeking a short squeeze [1] Group 1: Reasons for Heavy Shorting - Stocks become heavily shorted when experienced traders and institutional investors believe the company is fundamentally overvalued, anticipating a price drop [2] - Short sellers are concerned about significant risks such as poor earnings, failing business models, or industry headwinds that could negatively impact stock prices [2] Group 2: Retail Trader Perspective - Retail traders often see high short interest as a potential for a short squeeze, where rising stock prices can lead to rapid upward movements [3] Group 3: Short Squeeze Mechanics - A short squeeze occurs when a stock's price unexpectedly rises, forcing short sellers to buy shares to cover their positions, creating a feedback loop that drives prices even higher [4] - The volatility associated with a short squeeze can result in returns that significantly exceed typical stock movements within a short timeframe [5] Group 4: Most Shorted Stocks - A list of the most heavily shorted stocks is provided, focusing on those with market caps above $2 billion and free floats above 5 million, ranked by short interest as a percentage of shares available for public trading [6]

Group 1: Company Strategy and Product Development - Novo Nordisk plans to start selling its obesity drug Wegovy in vials, aiming to strengthen its market position against Eli Lilly as competition in the weight-loss market intensifies [1] - The introduction of vials is part of Novo Nordisk's broader ambition to reach millions of people living with obesity, offering more flexible dosing options compared to prefilled pens [3] - Novo Nordisk is evaluating multiple device configurations for Wegovy, with some expected to launch this year and others at a later stage [3] Group 2: Market Competition and Performance - Eli Lilly's CEO stated that vials have become the most popular format for weight-loss therapy, accounting for roughly one-third of new patients starting any therapy [2] - Novo Nordisk has not disclosed pricing details for its vial format and plans to introduce vials in the U.S. first before expanding to other markets [2] - Novo Nordisk expects adjusted sales growth for 2026 to be -5% to -13% at constant exchange rates, attributed to lower realized prices and increased competition [4] Group 3: Legal and Stock Performance - Novo Nordisk filed a lawsuit against Hims & Hers earlier this week [5] - As of the publication date, Novo Nordisk's stock is down 0.82% at $48.34 [5]

THIS IS "THE CLOSE." KATIE: LIVE FROM STUDIO 2, I'M KATIE GREIFELD. >> I'M SCARLET FU. LET'S GET A CHECK.ON THIS TUESDAY. KATIE: IT'S WEDNESDAY. SCARLET: IT IS.MAYBE THAT IS WHY EVERYTHING IS SO CONFUSING, JOBS REPORT WAS DELAYED BECAUSE OF THE PARTIAL GOVERNMENT SHUTDOWN. RIGHT NOW, THE S&P IS HIGHER. THAT JANUARY JOBS REPORT CAUSED TRADERS TO REPRICE THE TIMING OF WHEN THE FED RESUMES RATE CUTS LATER IN THE YEAR.THEY ARE CERTAINLY MORE SENSITIVE TO RATE CUTS. YOU SAW MOVEMENT IN THE TREASURY MARKET, TREAS ...

Core Viewpoint Novo Nordisk is facing significant challenges in the U.S. market due to competition from Eli Lilly and the rise of cheaper compounded versions of its weight-loss drug Wegovy. CEO Mike Doustdar has outlined a comprehensive strategy to navigate these challenges and aims for growth in 2026 despite the current headwinds. Group 1: Market Challenges - Novo Nordisk risks being edged out by Eli Lilly and the increasing number of patients using cheaper compounded versions of semaglutide, which are unapproved copies of Wegovy [2][8] - The company estimates that 1.5 million Americans are currently using these copycat weight-loss drugs, impacting its sales growth [8][12] - Doustdar acknowledged the challenges but expressed optimism for growth in 2026, stating that the company will have more patients and produce more than in previous years [3][7] Group 2: Product Performance - Approximately 246,000 patients are currently on Wegovy, which has outpaced the early rollouts of existing GLP-1 injections [5] - The Wegovy pill has shown an average weight loss of around 16.6%, compared to approximately 12.4% for Lilly's oral drug, indicating a significant efficacy advantage [20][27] - Doustdar emphasized that 88% of patients on the Wegovy pill are taking the lowest starter dose, suggesting a demand for oral options [18] Group 3: Competitive Landscape - Eli Lilly holds about 60% of the branded GLP-1 market globally, while Novo has around 39%, highlighting a competitive gap [16] - The compounded market shows a higher share of copycats for Novo's drug compared to Lilly's, raising questions about market dynamics [17] - Novo is preparing for increased competition as Lilly plans to launch its own oral weight-loss pill, orforglipron, in the second quarter of 2026 [19] Group 4: Regulatory and Legal Actions - Novo has initiated over 130 lawsuits against pharmacies and wellness clinics unlawfully marketing compounded versions of its drugs [12] - The FDA has announced a crackdown on compounding, which could potentially help Novo regain market share if successful [14][24] - Doustdar welcomed the government's acknowledgment of the compounding issue, viewing it as a strong signal for the company's efforts [14] Group 5: Future Strategies - Novo anticipates Medicare coverage for weight-loss treatments, which could open up a 15 million-patient opportunity [25] - The company is also focusing on next-generation treatments, including a higher dose of Wegovy and a new drug called CagriSema, which combines semaglutide with cagrilintide [26][28] - Doustdar believes that the higher dose of Wegovy could help the company compete more effectively against Lilly's Zepbound [27]

The race to offer cheaper weight loss drugs is running into some legal limits. Telehealth company Hims & Hers announced a cheaper version of Novo's Wegovy weight-loss pill at the beginning of February. Now it would cost $49 to start, which is far less than the $149 Novo sells the branded pill for.But it pulled the drug after legal and regulatory risks escalated. Now, legally, they're allowed to create a compounded version of a drug if they are saying they're adjusting the formula for "personalized purposes. ...

Group 1 - The U.S. stock market opened lower, with the Dow Jones down 0.14%, while the Nasdaq rose by 0.11% and the S&P 500 increased by 0.18% [1] - Weight loss drug stocks saw a general increase, with Novo Nordisk rising over 6% and Eli Lilly up more than 2%. In contrast, Hims & Hers, facing a lawsuit for infringing on the patent of semaglutide, dropped 24% [1][3] - Novo Nordisk filed a lawsuit against Hims & Hers for allegedly misleading consumers about the clinical benefits and safety of its compounded semaglutide products, which are produced using unregulated raw materials [3] Group 2 - The FDA informed Novo Nordisk that the advertising for its weight loss drug Weeovy is either false or misleading [4] - Nvidia's stock rose by 3.31%, with a market capitalization increase of approximately $477.74 billion (around 3.31 trillion RMB) over two trading days [4] - AI application software stocks experienced a rebound, with Roblox rising over 9%, Applovin up more than 8%, and Unity Software increasing by nearly 8% [11]